Published in J Chromatogr on November 24, 1993
Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target (2005) 1.12
Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer (1998) 1.06
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol (2007) 0.96
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection. BMC Clin Pharmacol (2006) 0.94
Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release (2011) 0.93
Release kinetics study of poorly water-soluble drugs from nanoparticles: are we doing it right? Mol Pharm (2015) 0.88
Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech (2011) 0.86
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat (1982) 2.98
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A (1997) 2.91
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol (2002) 2.90
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst (2000) 2.73
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res (1996) 1.95
Improved reagent for trimethylsilylation of sphingolipid bases. J Lipid Res (1967) 1.90
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol (2002) 1.78
Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med (1997) 1.75
Survival after massive ecstasy overdose. J Toxicol Clin Toxicol (1998) 1.75
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol (2001) 1.70
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol (2003) 1.65
Taxanes: a new class of antitumor agents. Cancer Invest (1995) 1.62
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis (2001) 1.62
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS (2000) 1.56
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol (1993) 1.51
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J Clin Oncol (1999) 1.48
Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest (1997) 1.48
Preparation and stability testing of a hydrogel for topical analgesia. Pharm World Sci (1995) 1.47
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer (2001) 1.45
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol (1996) 1.45
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer (1999) 1.45
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol (1999) 1.43
Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol (2002) 1.42
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 1.40
[Severe phenytoin intoxication in patients with hypoalbuminaemia]. Ned Tijdschr Geneeskd (2007) 1.40
[Pleurodesis in malignant pleural effusion]. Ned Tijdschr Geneeskd (1997) 1.39
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer (2012) 1.38
Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244) J Pharm Sci (1996) 1.38
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr (2001) 1.37
Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol (1998) 1.35
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. J Mass Spectrom (2006) 1.34
Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum (2000) 1.32
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem (2001) 1.31
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol (2001) 1.30
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer (2002) 1.30
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res (2001) 1.29
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem (2011) 1.29
Antiretroviral drugs and the central nervous system. AIDS (1998) 1.28
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther (2006) 1.27
Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs (1996) 1.27
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses (2006) 1.26
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol (1997) 1.25
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther (2001) 1.24
Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide. J Pharm Sci (1980) 1.24
Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS (1993) 1.23
The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev (2007) 1.23
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs (2001) 1.22
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2002) 1.22
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst (1996) 1.21
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos (2001) 1.20
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol (2006) 1.20
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer (2006) 1.16
Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs (2001) 1.16
Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Pharm World Sci (1995) 1.16
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol (2009) 1.16
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol (2005) 1.16
Alternative formulations of paclitaxel. Cancer Treat Rev (1997) 1.14
Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl (1998) 1.13
Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry (1994) 1.13
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res (1999) 1.12
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet (2001) 1.12
Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol (2000) 1.12
Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol (1996) 1.11
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res (1999) 1.11
Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis (1999) 1.11
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl (1995) 1.11
Chemistry and metabolism of sphingolipids. 3-Oxo derivatives of N-acetylsphingosine and N-acetyldihydrosphingosine. J Am Chem Soc (1966) 1.10
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci (1997) 1.10
Propofol extravasation in a breast cancer patient. J Oncol Pharm Pract (2008) 1.08
[Miltefosine: a new remedy for leishmaniasis]. Ned Tijdschr Geneeskd (2006) 1.08
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol (2002) 1.07
Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol (1994) 1.07
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther (2004) 1.07
The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci (1997) 1.07
Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.06
Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet (1998) 1.06
Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother (1993) 1.06
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer (1997) 1.06
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl (1998) 1.06
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer (2002) 1.05
Drug interaction between St John's wort and nevirapine. AIDS (2001) 1.05
Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev (2006) 1.05
Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med (1998) 1.04
Clinical pharmacokinetics of topotecan. Clin Pharmacokinet (1996) 1.03
Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci (2000) 1.01
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl (1995) 1.01
The mechanism of voltage-sensitive dye responses on sarcoplasmic reticulum. J Membr Biol (1981) 1.00
Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob Agents Chemother (1996) 0.99
Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces. Proc Natl Acad Sci U S A (1999) 0.99
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer (1998) 0.99
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer (2001) 0.99
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res (1998) 0.99
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Lab Anim (2003) 0.98
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl (1996) 0.98
Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med (1994) 0.97